Can-Fite BioPharma Ltd. (TLV:CANF)
1.000
0.00 (0.00%)
At close: Nov 27, 2025
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $101.00K USD in the half year ending June 30, 2025, a decrease of -36.08%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm)
$560.00K
Revenue Growth
-16.04%
P/S Ratio
27.15
Revenue / Employee
$112.00K
Employees
5
Market Cap
51.22M ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
| Dec 31, 2015 | 162.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 55.55B |
| Danel (Adir Yeoshua) | 2.87B |
| Novolog (Pharm-Up 1966) | 2.06B |
| Ilex Medical | 927.57M |
| Kamada | 578.74M |
| SofWave Medical | 255.13M |
| InterCure | 243.12M |
| BrainsWay | 162.56M |
Can-Fite BioPharma News
- 5 days ago - Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025 - GuruFocus
- 9 days ago - Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment - GuruFocus
- 9 days ago - Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil - GlobeNewsWire
- 10 days ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News - GuruFocus
- 11 days ago - Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival - GuruFocus
- 25 days ago - CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News - GuruFocus
- 2 months ago - CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News - GuruFocus
- 2 months ago - Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment - GuruFocus